推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733，021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

Long-term results of fludarabine/melphalan as a reduced-intensity conditioning regimen in mantle cell lymphoma: the GELTAMO experience

J Gayoso, R Martino, P Balsalobre… - Therapeutic …, 2011 - tah.sagepub.com
Abstract: Background: We herein report the long-term results of an allogeneic reduced-intensity
con- ditioning (allo-RIC) protocol used in 21 consecutive patients (16 males, median age 56
years, 71% in complete remission) diagnosed with mantle cell lymphoma (MCL). ...
All 2 versions

[PDF] Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.

[PDF] from hematologylibrary.orgMT Cibeira, V Sanchorawala… - …, 2011 - bloodjournal.hematologylibrary.org
Page 1. 1 Outcome of AL Amyloidosis after High-dose Melphalan and Autologous Stem Cell ... 3
ABSTRACT Previous studies have suggested that in patients with AL amyloidosis treated with
high- dose melphalan and autologous stem-cell transplantation (HDM/SCT), the greatest ...
View as HTML

Alkylating chemotherapeutic agents cyclophosphamide and melphalan cause functional injury to human bone marrow-derived mesenchymal stem cells

K Kemp, R Morse, K Sanders, J Hows… - Annals of hematology, 2011 - Springer
Abstract The adverse effects of melphalan and cyclophos- phamide on hematopoietic stem cells
are well-known; however, the effects on the mesenchymal stem cells (MSCs) residing in the bone
marrow are less well characterised. Examining the effects of chemotherapeutic agents on ...
Cited by 1 - Related articles - All 5 versions

High-dose melphalan followed by ASCT has favorable safety and efficacy in selected patients with light chain deposition disease and light and heavy chain deposition …

D Telio, J Shepherd, D Forrest, L Zypchen… - Bone Marrow …, 2011 - nature.com
Light chain and light and heavy chain deposition disease (LCDD and LHCDD) are plasma cell
dyscrasias in which aggregation and deposition of Ig components leads to organ
dysfunction. Although similar in principle to light chain (AL) amyloidosis, there are a ...
Cited by 1 - All 3 versions

Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis

P Kapoor, SV Rajkumar, A Dispenzieri, MA Gertz… - Leukemia, 2011 - nature.com
Trials comparing efficacy of melphalan prednisone (MP) with MP plus thalidomide in transplant
ineligible, elderly patients with multiple myeloma have provided conflicting evidence. Although
there is agreement regarding improved response rates (RRs) and higher toxicity with the ...
Cited by 8 - Related articles - All 4 versions

联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

© 2010-2024 中国: LetPub上海分公司    网站备案号：沪ICP备10217908号-1    沪公网安备号：31010402006960

增值电信业务经营许可证：沪B2-20211595

礼翰商务信息咨询（上海）有限公司      办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室

United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451